Fibrodysplasia Ossificans Progressiva
INCYIncyte CorporationCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Zilurgisertib (ALK2 Inhibitor) in Fibrodysplasia Ossificans Progressiva. The expected timing is based on the latest available company guidance and may change.
06/04/26:- PROGRESS Ph2 Cohort 1 results at ENDO 2026 (Jun 13–16). PDUFA Sep 26, 2026. 06/14/26:- NDA accepted with Priority Review; PDUFA Sep 26, 2026. PROGRESS Week 48 Cohort 1 data presented.
Verification
Confirm timing and program details against the company announcement or filing.